Management of Brain Metastases in Melanoma: An Overview of COMBI-MB and CheckMate 204

Management of Brain Metastases in Melanoma: An Overview of COMBI-MB and CheckMate 204

AnnualMeeting2017

3 years
481 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Manmeet S. Ahluwalia, MD of Cleveland Clinic discusses three abstracts presented at ASCO 2017, highlighting the management of brain metastases in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9506: COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600mutant (mut) melanoma brain metastases (MBM) presented by Dr. Michael A. Davies of MD Anderson Cancer Center Abstract 9507: Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204 presented by Dr. Hussein Abdul-Hassan Tawbi of MD Anderson Cancer Center Abstract 9508: A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC) presented by Dr. Georgina V. Long of University of Sydney
Up Next Autoplay